BVT Knock-Out BMY/ DE000VX9JAH2 /
11/13/2024 1:40:00 PM | Chg.0.00 | Bid2:23:47 PM | Ask2:23:47 PM | Underlying | Strike price | Expiration date | Option type |
---|---|---|---|---|---|---|---|
2.07EUR | 0.00% | 2.10 Bid Size: 31,000 |
2.12 Ask Size: 31,000 |
Bristol Myers Squibb... | 81.16 USD | 12/31/2078 | Put |
GlobeNewswire
9/2
CSE Announces its 2024 Sustainability & ESG Leadership Summit at NYC's One World Trade Center
GlobeNewswire
8/30
Purple Biotech to Participate at H.C. Wainwright 26th Annual Global Investment Conference
GlobeNewswire
8/28
Hematologists Highlight Ongoing Challenges in Sickle Cell Disease and Thalassemia Amidst Promising A...
GlobeNewswire
8/22
Abata Therapeutics Receives FDA Fast Track Designation for ABA-101 for the Treatment of Progressive ...
GlobeNewswire
8/15
Abata Therapeutics Announces Strategic Investment from Bristol Myers Squibb Supporting Advancement o...
GlobeNewswire
8/12
Altamira Therapeutics Announces Significant Enhancement of Immune Checkpoint Inhibition Therapy in C...
Newsfile Corp
8/12
The Cancer Battle - How Smaller Companies Are Making Big Advancements in Treatments for Solid Tumors
GlobeNewswire
8/8
CytomX Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update
GlobeNewswire
8/7
Efficacy and Safety Data of Sotagliflozin in Patients with Type 1 Diabetes and Chronic Kidney Diseas...
GlobeNewswire
8/5
iTeos Therapeutics Announces Appointment of David Feltquate as Chief Medical Officer
GlobeNewswire
8/1
Outpace Bio Announces $144M Oversubscribed Series B Financing to Advance AI-powered Cell Therapies i...
GlobeNewswire
8/1
CytomX Therapeutics to Report Second Quarter 2024 Financial Results on August 8, 2024
GlobeNewswire
7/31
Mural Oncology Appoints Veteran Business Development Executive George Golumbeski, Ph.D., to its Boar...
GlobeNewswire
7/25
Purple Biotech Receives Extension to Regain Compliance with the Nasdaq’s Minimum Bid Price Rule
GlobeNewswire
7/24
Prota Therapeutics Strengthens Board with Appointment of Global Biotech Expert Patrick Machado
GlobeNewswire
7/20
NCLA Asks Third Circuit to Rule Against HHS’s Coercive Medicare Drug Price ‘Negotiation’ Program